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Abstract
B cells are an integral component in mounting humoral immune responses and they are also crucial in programming T cell
mediated immunity. Usually, B cell activation is initiated by recognition of antigen through B cell receptor (BCR), followed by
its processing and presentation to T cells. But very little is known about BCR independent activation of B cells. Now, there is
an increasing body of evidence indicating the combinatorial effect of innate and adaptive immune components in
modulating the functions of B cells. In this study, we demonstrate the activation of resting B cells (RB) by simultaneous
involvement of Toll like Receptor-2 (TLR-2) and costimulatory molecule, CD86. Interestingly, these B cells exhibited
significant level of activation and proliferation. Furthermore, this process of activation leads to the differentiation of RB cells,
preferably into marginal zone precursors (CD19+IgDhiIgMhiCD21/35hiCD23hi) in a shorter time window and showed
increased secretion of IgG isotype. These RB cells also showed enhanced antigen uptake capacity. These observations were
also substantiated by microarray gene expression results, which strengthen the notion that combinatorial signaling through
innate and adaptive immune components enhances B cell mediated immune response. Thus, the present study elucidates a
novel BCR independent B cell activation mechanism that links TLR-2 and CD86. Hence signaling of TLRs in conjunction with
costimulatory molecules will substantially help in bolstering humoral immune response, which can be extrapolated to
formulate vaccination strategies for diseases involving B cell-mediated immunity.
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Introduction
It is widely established that two signals are needed for the
optimal activation of T cells. Signal-1 involves interaction of
antigen specific T cell receptor (TCR) with peptide-major
histocompatibility complex (MHC) molecules on the surface of
antigen presenting cells (APCs). Signal-2 is also APC driven and
engages interaction of costimulatory molecules, mainly CD80 and
CD86 with CD28 and CTLA-4 that are expressed on T cells [1–
3]. The role of costimulatory molecules is well established in the
context of T cell activation but not much is known in the case of B
cells [4–6]. Recently, much evidence has been generated
indicating the role of costimulatory molecules in influencing the
functions of APCs through bi-directional signaling [7–11].
Among the various costimulatory molecules studied, the role of
CD86 has been prominently elucidated in affecting the functions
of B cells. Direct triggering of B cells through CD86 enhances
proliferation, secretion of IgG1 and IgG2a and their survival by
augmenting the expression of anti-apoptotic molecules [11]. In
addition, cross linking of CD86 on human B cells that are
stimulated in vitro with CD40 and cytokines enhances secretion of
IgE and IgG4 [1]. Similarly, IL-4/CD40 stimulated B cells are
synchronously regulated by signaling through CD86 and 2-
andregenic receptor. Such B cells exhibit enhanced activation and
expression of Oct-2, NF-kB and 39-H enhancer and have
augmented capacity of antibody secretion [9–14]. In vivo studies
have shown that CD86 induces the differentiation of already
isotype switched B cells to antibody secreting plasma cells through
up regulation of XBP-1 [3]. Further, the role of CD86 has also
been demonstrated in germinal center formation and primary
humoral response [15]. Moreover, the structural conformation
and valence of CD86 confers high affinity for CD28 and therefore
it is a preferred ligand over CTLA-4. Interaction of CD86 with
CD28 delivers positive signals for T cell and B cell activation
[16,17].
The expression of costimulatory molecules such as CD86 and
CD80 on B cells is also augmented by their stimulation through
Toll-like receptors (TLRs) [18–20]. TLRs are evolutionarily
conserved germline encoded molecules that play a key role in
regulating innate immune responses. TLRs have gained consid-
erable impetus in influencing the biology of B cells such as their
activation, differentiation, antibody secretion and class switch
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recombination [2,19,21,22]. Recent evidence indicates a concur-
rent effect of molecules of innate immunity such as TLRs and
adaptive immunity like BCR, CD38 in the activation and
differentiation of B cells. For example, we have recently
demonstrated that concerted signaling through CD40 and TLR-
2 induces B cell activation and improves their antigen presentation
in a BCR-independent manner [7]. Moreover, signaling through
TLRs and CD38 or BCR cooperate with each other in inducing
activation of B cells [23–25]. In addition, sequential signaling
through TLR-7 and BCR breaks the tolerance in B cells [26].
Several ligands such as lipoproteins, macrophage-activating
lipopeptide-2, neisserial porins, pneumococcal surface adhesin A
(PsaA) etc., have been reported to activate B cells through
engagement of TLR-2 [27,28]. The role of TLR-2 on B cells has
been implicated in regulating humoral immune responses, in
particular, mediating in vivo primary humoral immune response
[29]. To the best of our knowledge, there is no published evidence
indicating the combinatorial effect of CD86 and TLR-2 in
regulating the activation of resting B (RB) cells.
In the present study, we have investigated the impact of CD86
costimulation in bolstering the function of TLR-2 elicited RB cells.
Our results indicate that this strategy of signaling leads to
substantial increase in the activation, differentiation and antigen
uptake capacity of RB cells.
Results
CD86 costimulation enhances the activation of TLR-2
stimulated RB cells
We first investigated the impact of CD86 and TLR-2
costimulation (TLR2.CD86) on RB cells (Fig. 1A). We observed
that TLR2.CD86 stimulation results in an augmented expression
of activation markers such as CD21/35, CD23 and IgM. The
expression of IgD was downregulated, signifying that these two
signals exert conjoining effects on RB cells leading to their
activation necessary to counteract antigens. Steady-state equilib-
rium in RB cells activation is obtained by moderate enhancement
in the expression of CD5 and increased expression of CD19 as well
as CD21/35. This indicated an improved CD19-mediated
signalosome activity that results in reduced threshold of B cell
activation. These results correlated well with the microarray gene
expression data showing enhanced expression of genes coding for
B cell activation markers such as cd21/cd35, cd23, cd19, cd25 and
cd40 (Fig. 1B). Moreover, upregulated expression of Cd25 and
Cd40 genes indicate mature and activated phenotype. The
expression of Gapt gene was found to be reduced on TLR2.CD86
costimulation. Gapt codes for GRB-2 protein, which is a negative
regulator of B cell proliferation and survival. An enhancement in
the size, proliferation and blast formation was also observed in RB
cells upon TLR2.CD86 stimulation (Fig. 1C, Fig. S1, Fig. S2).
Kinetics of forward scatter (FSC modulation) revealed that dual
signals start affecting the size as early as 4 h and peaked at 16 h
(FSC: 4657962534 vs.7801764472). Taken together, these
findings suggested that CD86.TLR2 signals drive B cell matura-
tion and activation.
Simultaneous signaling through CD86 and TLR-2
enhances the survival of RB cells
A decreased expression of Gapt gene prompted us to investigate
the role of TLR2.CD86 signaling in the survival of RB cells. We
stimulated RB cells for 48 hours through both the signals and
found that the percentage of cells undergoing apoptosis was
drastically reduced when RB cells were stimulated through both
CD86 and TLR-2 simultaneously (Fig. 2A, 2B). This further
indicated that TLR2. CD86 signaling promotes the survival of RB
cells [7,11]. This observation was supported by microarray data,
where we observed that RB cells triggered through TLR2.CD86
had an enhanced expression of genes encoding anti-apoptotic
molecules (Bcl21a, Pim2, Lrdd), transcription factors (Gata6),
cytokines and their receptors (Il2ra and Ifn), and B cell activation
factors (Nfkbid). TLR2.CD86 also led to reduced expression of
genes encoding pro-apoptotic factors (Pten, capase-7, capase-3)
and apoptosis related genes (Pmaip1,P2rx7, Rnf family of proteins,
Dock1, Apaf1, Ddit) (Fig. 2C). Thus, these results suggested that
signaling through TLR2.CD86 enhances the survival of RB cells.
TLR2.CD86 signaling drives RB cell differentiation to
marginal zone precursors
As stated previously, TLR2.CD86 signaling leads to an
enhanced expression of Gata6 gene. This indicated that these
signals have impact on terminal B cell differentiation and
proliferation. Hence we examined the outcome of TLR2.CD86
stimulation on differentiation of RB cells. We noted that
TLR2.CD86 stimulated RB cells preferentially differentiate into
marginal zone precursors (MZP; CD19+IgDhiIgMhiCD21/
35hiCD23hi), which may later form marginal zone cells. We
observed a substantial enhancement in the percentage of MZP
cells (10% to 36% at 48 h) when RB cells were stimulated through
TLR2.CD86 (Fig. 3A, Fig S3). This enhancement was observed
from an early time (24 h), indicating that TLR2.CD86 signals
reduce the differentiation period/window of RB cells. In support
of this finding, we observed upregulated gene expression of Clcf1,
a neurotrophic factor that activates JAK/STAT pathway, which is
involved in B cell activation and differentiation (Fig. 3B). The
significance of this observation lies in the fact that MZ B cells are
non-circulating mature cells that can be rapidly recruited in an
early adaptive immune response in a T cell dependent manner.
These are innate B cells with a lower activation threshold and a
higher propensity of differentiation into plasma cells, thereby
further accelerating primary antibody response [30]. TLR2.CD86
signaling of RB cells amplifies this population, thereby further
aiding in their transformation into plasma cells and antibody
secretion. Hence, TLR-2 and CD86 not only bridge innate and
adaptive immunity but also amplify the magnitude of immune
responses, which may help in boosting the B cell-mediated
immune response.
Stimulation through TLR2.CD86 boosts antibody
secretion and class switch recombination of RB cells
We observed that TLR2.CD86 signaling preferentially trans-
forms RB cells into MZP which, in turn, promotes differentiation
of plasma cells. Hence it was imperative to assess the role of
TLR2.CD86 signaling in immunoglobulin secretion and class
switch recombination (CSR). TLR2.CD86 stimulated RB cells
secreted elevated levels of IgM and IgG1 (Fig. 4A, B). The ratio of
CSR in such cells was calculated as the ratio of surface expression
of IgG1 to IgM. TLR2.CD86 stimulated RB cells showed
enhanced CSR ratio. This indicated that TLR2.CD86 signals
are effective in CSR (Fig. 4C). This response was significantly
better than that observed in the control cells stimulated
individually through TLR-2 or CD86. Thus, it may be inferred
that RB cells acquire improved levels of activation and maturation
and secrete elevated levels of immunoglobulin isotypes when
activated through TLR2.CD86.
B Cell Activation through TLR-2 and CD86
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TLR-2.CD86 stimulated RB cells have enhanced antigen
uptake abilities
We next monitored whether TLR2.CD86 stimulated RB cells
gain improved antigen uptake through pinocytosis and receptor
mediated endocytosis. We observed that TLR2.CD86 stimulated
RB cells acquired enhanced pinocytotic ability when pulsed with
horse radish peroxidase (HRP), as a soluble antigen (Fig. 5A).
Further, TLR2.CD86 stimulated RB cells also showed marked
increase in receptor-mediated endocytosis of anti-mouse IgG-HRP
antibody. This response was significantly better than the controls
where signal was delivered through TLR-2 or CD86 individually
(Fig. 5B). Enhanced antigen uptake by TLR2.CD86 stimulated
RB cells may also be due to augmented expression of Rab genes,
which are responsible for actively promoting endocytosis. In
addition, we also observed upregulation in genes such as Pascin2
and Stab2, which are involved in tubulin polymerization,
rearrangement of cytoskeleton and endocytosis of low density
antigens (Fig. 5C). Hence, we concluded that TLR2.CD86
signaling not only improves the activation and maturation of RB
cells, but also enhances their antigen uptake ability.
Figure 1. CD86 synergizes with TLR-2 in enhancing the size and activation of RB cells. (A) RB cells from BALB/c mice were stimulated by
anti-CD86 Ab and Pam2CSK4 and checked for the expression of CD21/35, IgD, CD5, IgM, CD23 and CD19. Numbers in the flowcytometry plots
represent mean fluorescence intensity (MFI) of respective markers; (B) microarray data indicates geometric mean of the fold change in the expression
of genes encoding for activation markers. Data are representative of two biological replicates. Statistical analysis was done using One Way ANOVA; (C)
change in cell size (FSC) was assessed by flowcytometry. Flowcytometry data (A, C) expressed as mean6SEM are representative of 3–5 independent
experiments and statistical analysis was done by Student‘t’ test. ‘*’, ‘**’, ‘***’ indicates p,0.05, p,0.01, p,0.001, respectively.
doi:10.1371/journal.pone.0054392.g001
Figure 2. Concomitant signaling of CD86 and TLR-2 reduces the percentage of RB cells undergoing apoptosis. RB cells isolated from
BALB/c splenocytes were stimulated by anti-CD86 Ab and Pam2CSK4 for 72 h and apoptosis was checked by PI-Annexin V staining. (A)
Flowcytometry density plots show the representative PI-Annexin double positive cell population; (B) bar diagrams indicate percentage change in PI-
Annexin double positive population with respect to controls (PI-Annexin double positive cells of unstimulated cells taken as 100%). Flowcytometry
data expressed as mean6SEM were representative of 3 independent experiments. Statistical analysis was done by Student‘t’ test and ‘**’, ‘***’
indicate p,0.01 and p,0.001 respectively; (C) dendrograms represent modulation in the expression of genes encoding for molecules involved in
apoptosis. Left panel indicates upregulated genes, whereas right panel signify downregulated genes. Scale bar: 22 to +2.
doi:10.1371/journal.pone.0054392.g002
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Discussion
In the current state of events, expanding evidence indicates
synchronous functioning of molecules responsible for modulating
innate and adaptive immune response. Studies have shown that
various components of immune system like NK cells, dendritic
cells, TLRs, complement system, glycans and defensins play a
fundamental role in bridging the innate and adaptive immune
response.
Recently, we have demonstrated that CD40 and TLR-2
combine to bring together the adaptive and innate arms of the
immune system [7]. Yet, the nexus of innate and adaptive
immunity still curtails many facets. Ongoing efforts are directed to
explore new molecules or to define novel roles of already
established molecules that can further cement the gap between
these two limbs of immune system.
In a continual pursuit, we report here a unique role of
combinatorial signaling through TLR-2 and CD86 in modulating
the functions of RB cells. Our major findings suggest that
TLR2.CD86 stimulated RB cells exhibit upregulated expression
of activation markers and enhanced survival. Such RB cells
differentiate into marginal zone precursors and express enhanced
class switch recombination. Moreover, they also have improved
ability of antigen uptake. Our studies involved highly enriched RB
cells with no contaminating T cell populations. This ruled out any
possibility of T cell mediated B cell activation. Moreover, because
we used Pam2CSK4 ligand and anti-CD86 antibody for signaling
to ensure that the observed experimental outcomes were solely due
to signaling through TLR-2 and CD86. These findings suggest a
distinct possibility for the existence of BCR-independent pathway
for activation of B cells by costimulatory molecules and TLRs.
Our findings also demonstrate the cooperative role of the
molecules of innate and adaptive immunity in activating RB cells.
Signaling through CD86 has positive effects on B cell functions
in terms of their proliferation, immunoglobulin isotype secretion
and survival [3,7,11,14]. The expression of CD86 is enhanced on
B cells following their stimulation with TLRs [18]. Moreover,
TLRs also play an instrumental role in boosting the functions of B
cells [2]. There is an increasing body of evidence, which indicates
that simultaneous signaling through TLRs and molecules of innate
immunity such as CD38 induce strong proliferative and activation
signals in B cells [31]. In line with these observations and our own
findings, which infer that CD40 also synergizes with TLR-2 in
augmenting B cell activity [7], we further sought to ascertain the
effect of concomitant signaling through CD86 and TLR-2 on RB
cells. Intriguingly, we found that such stimulation could bolster the
activation status of B cells in terms of enlargement of size and
expression of activation markers such as CD21/35, CD23 and
CD19. The activation process does not happen in a slap dash or
haphazard manner because there is slight upregulation in the
expression of negative regulators of B cells such as CD5. Thus, the
entire plethora of molecules such as CD23, CD21, IgM, IgD,
CD5, etc., aid in maintaining the immune homeostasis, which
indicates that these signals evoke events that are responsible for
regulated activation of RB cells. As such, RB cells have little
costimulatory activity as compared to mature B cells due to lesser
expression of CD86. Yet, signaling through CD86 can result in an
enhanced activated phenotype. When this signaling is coupled
with another positive modulator, such as TLR-2, both function
conjunctively to modulate the activity of B cell.
Concurrent signaling through CD86 and TLR-2 also led to B
cell differentiation into marginal zone precursors (MZP). These
MZP later differentiate into marginal zone cells that again act to
connect innate and adaptive immunity. The lower threshold of
activation of marginal zone cells and their easy propensity to
differentiate into plasma cells makes them suitable for effector
Figure 3. Simultaneous signaling through CD86 and TLR-2 preferentially differentiates RB cells into marginal zone cells. Signaling
was delivered in RB cells isolated from BALB/c with anti-CD86 Ab and Pam2CSK4. (A) Bar diagrams show marginal zone precursors (CD19+,
IgDhiIgMhiCD21/35hiCD23hi) in differentially stimulated RB cells at 24 h and 48 h. Values indicate the mean6SEM of percent populations of
IgDhiIgMhiCD21/35hiCD23hi expressing cells. Data are representative of three independent experiments. Statistical analysis was done by Student‘t’
test. ‘*’, ‘**’, ‘***’ indicates p,0.05, p,0.01, p,0.001, respectively. (B) Dendrograms depict upregulation in genes involved in differentiation of RB cells
with respect to unstimulated controls in different color codes (yellow: no change, red: upregulation, green: downregulation). The values indicate
geometric mean of fold change of two of the biological replicates.
doi:10.1371/journal.pone.0054392.g003
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function, in a lesser time span. It also leads to enhanced
maturation of RB cells, which undergo more class switch
recombination and secrete elevated levels of immunoglobulin
isotypes. This convinced us to put forward a novel concept that
combined triggering of TLR-2 and CD86 can elicit enhanced
secretion of antibodies, thereby boosting humoral immunity.
The inherent ability of B cells to act as antigen presenting cells
(APC) is usually remote. They cannot uptake, process and present
antigen as efficiently as dendritic cells. Signaling through CD86
and TLR-2 augmented the ability of B cells to acquire antigen
through both fluid-phase pinocytosis and receptor-mediated
endocytosis. These observations gave clear implications that
CD86 and TLR-2 can act in cohort to not only achieve optimum
activation functions of B cells, but also to improve their role as
APC. This study, therefore, demonstrates that CD86 in association
with TLR-2 can trigger B cells in a BCR independent fashion. We
propose a novel role of simultaneous signaling through CD86 and
TLR-2 in RB cells to significantly improve their functions as
humoral mediators of immune response as well as antigen
presenting cells. Our findings open avenues to investigate the
molecular mechanisms involved in the dynamics of such concur-
rent signaling that may decipher these results more comprehen-
sively. Finally, triggering through TLR2 and CD86 can be
employed in bolstering the efficacy of B cell-mediated vaccines.
Conclusions
The present study indicates that there exists a flexible
continuum between molecules of innate and adaptive immunity
and both of them work in concert to maintain a homeostatic
harmony. Simultaneous signaling through CD86 and TLR-2
unravels a unique BCR independent mechanism of activating
resting B cells. Cells stimulated in this manner have an enhanced
longevity, activation profile, differentiation status and ability to
uptake antigen. The data are in agreement with the gene
expression profiles and insinuates to further decipher the
molecular mechanism behind this concurrence. An insight into
the detailed mechanism may pave way to design vaccines based on
this signaling strategy.
Methods
Ethics statement
Male or female BALB/c, C57BL/6 and C3He mice of 6–8
weeks were procured from National Institute of Immunology, New
Delhi and National Institute of Pharmacological Education and
Research, Mohali and National Institute of Nutrition, Hyderabad,
India. All animal studies were approved by the Institutional
Animal Ethics Committee of Institute of Microbial Technology
(Ref. No 55/1999/CPCSEA), India.
Reagents
B cell cocktails, biotin-conjugated anti-mouse CD43 (S7),
CD45R (B220, RA3-6B2), CD40 (3/23), isotype control
(IgG2ak,R35-95), CD23 (B3B4); PE-labeled anti-mouse IgD (11-
26c.2a), CD86 (GL1); PE-Cy5 conjugated CD5 (53-7.3), PE-Cy7
coupled IgM (R6-60.2); APC or PE-Cy5 conjugated streptavidin;
APC-Cy7 linked CD19 (1D3) and Pacific blue tagged CD45R
(B220, RA3-6B2) and all ELISA reagents were purchased from
BD Biosciences (San Diego, CA). TLR-2 ligand (Pam2CSK4) was
obtained from Invivogen (San Diego, CA). RPMI-1640 and FCS
were from Gibco (Grand Island, NY). All other standard reagents
were procured from Sigma (St. Louis, MO), unless otherwise
mentioned.
B cell isolation and stimulation
RB cells were purified from mice (BALB/c or C57BL/6)
splenocytes using CD43 negative B cell isolation method, as
Figure 4. CD86 show synergism with TLR-2 in augmenting the
secretion of IgM and IgG1 and class switch recombination. (A,
B) Supernatants from 5–6 days old cultures of RB cells isolated from
BALB/c mice and stimulated with anti-CD86 Ab and Pam2CSK4 were
harvested and assessed for the production of IgM and IgG1 by
sandwich ELISA. Data expressed as mg/ml represent mean 6 SEM of the
triplicate wells were calculated with respect to standards. (C) Ratio of
surface expression of IgG1 and IgM on RB cells stimulated with anti-
CD86 or isotype antibody in the presence or absence of Pam2CSK4 for
16 h. Data are representative of 3–4 experiments. (A, B, C) Statistical
analysis is done by non-parametric Mann-Whitney two tailed test and
repeated measure ANOVA with post Student-Newman-Keuls multiple
comparisons test by Graph Pad InStat 3 software. ‘p’ values are denoted
with respect to unstimulated controls. ‘*’, ‘**’, ‘***’ indicates p,0.05,
p,0.01, p,0.001, respectively.
doi:10.1371/journal.pone.0054392.g004
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described previously (7). Briefly, after preparing single cell
suspension, splenocytes were treated with B cell enrichment
cocktail supplemented with biotinylated anti-CD43 Abs. Later,
same volume of streptavidin-magnetic beads was added and RB
cells were negatively selected on BD IMagnet. The purity of RB
cells obtained was .98%, as ascertained by flow cytometry
(CD45R+CD19+CD432CD42CD82). Enriched RB cells were
incubated with biotin conjugated anti-CD86 Abs and isotype
matched control (IgG2a,k) (0.5 mg/106 cells) for 30 minutes on ice
followed by cross-linking with equivalent concentration of
streptavidin (0.5 mg/106 cells), under similar conditions. The cells
were cultured in RPMI-1640 (10% FCS) with specified concen-
tration of Pam2CSK4 (50 ng/ml). Appropriate controls such as
cells alone, cells stimulated with anti-CD86 Abs alone or isotype
matched Abs alone were also kept in all experiments.
Flow cytometry
Cells were stained with fluorochrome labeled anti-mouse CD21/
35, CD5, IgD, IgM, CD19 Abs and their respective isotype
matched controls, as described previously (7). Finally, cells were
washed and fixed in 1% paraformaldehyde. The flowcytometry
data was acquired on either on BD FACS Calibur or on BD FACS
Aria II using Cell Quest Pro (FACSCalibur) or FACSDiva software
(FACS Aria II). Data was analyzed by FACS Diva software, as
described previously (7). Flowcytometry data is either represented as
percentage population or as mean fluorescence intensity (MFI)
normalized with suitable isotype matched controls. FSC in
flowcytometry data represents cell size, depicted on a linear scale.
Isotype ELISA
Supernatants were collected from 5–6 day old cultures of RB cells
(26105 cells per well) after stimulation with anti-CD86 Ab (0.5 mg/106
cells) with or without Pam2CSK4 (50 ng/ml) and assayed for IgM and
IgG antibodies, as described previously (7). In brief, ELISA plates were
coated with purified rat anti-mouse IgM or IgG1Abs at 4uC overnight.
The plates were then washed 36with buffer (PBS+0.05% Tween-20)
and blocked with PBS+1% BSA for 2 h at room temperature and
washed again 36. Culture supernatants and serial dilutions of the
standards (purified mouse IgM or IgG1; log2 dilutions) were added in
these plates and incubated at 4uC over night. Plates were again washed
and bound IgM and IgG1 were captured by secondary biotinylated
anti-mouse IgM and IgG1 Abs, respectively, followed by their
detection with avidin-HRP/OPD-H2O2 for colorimetric estimation.
The concentrations of isotype antibodies secreted were calculated using
optical densities (ODs) of standard IgM and IgG1 as reference curves
and results were expressed as mg/ml.
Antigen uptake assay
Antigen uptake assays were performed according to the
methods described previously (7). In brief, signaling was delivered
in RB cells (26105/well) using anti-CD86 Abs (0.5 mg/106 cells) in
the presence or absence of Pam2CSK4 (50 ng/ml) for 16 h at
Figure 5. Triggering through CD86 and TLR-2 enhances pinocytosis and receptor mediated endocytosis abilities of RB cells. (A, B) RB
cells of BALB/c mice were stimulated with anti-CD86 Ab and Pam2CSK4 and pulsed with (A) soluble HRP and (B) anti-mouse IgG-HRP. The antigen
was chased at 37uC for 30 minutes and internalization of antigen was determined colorimetrically. Values shown in the graphs were normalized
against experimental blanks and control cells (maintained at 4uC and lysed). The data represents mean 6 SEM of one of the 2–3 individual
experiments. ‘*’, ‘**’, ‘***’ indicates p,0.05, p,0.01, p,0.001, respectively. (C) Dendrograms represent modulation in the expression of genes
encoding for molecules involved in endocytosis. Scale bar: 22 to +2.
doi:10.1371/journal.pone.0054392.g005
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37uC. The cells were harvested, washed and incubated with either
anti-mouse IgG-HRP Ab (1:100) or free HRP (200 mg/ml) and
incubated on ice for 15 minutes followed by culturing in RPMI-
FBS-5% at 37uC. Antigen uptake kinetics was done for 30–
60 minutes and was later stopped by adding chilled PBS. Cells
were washed thoroughly with ice cold PBS (containing 1% FBS)
and subsequently they were treated with pronase. The cells were
washed and lysed with a mixture of Tris-HCl (10 mM) and Triton
X-100 (0.05%) for 30 minutes on ice, with intermittent vortexing.
Intracellular HRP in the cell lysates was estimated colorimetrically
(at 492 nm) using OPD-H2O2 chromogen-substrate method. Cells
treated with pronase, cells maintained at 4uC, and unlysed cells
were taken as controls. The presence of HRP in the controls was
suitably normalized with test samples.
Propidium Iodide (PI) -Annexin Assay
The assay was performed according to standard procedures, as
described previously (7). In brief, RB cells (56104/well) were
stimulated with anti-CD86 Ab (0.5 mg/106 cells) in the presence or
absence of Pam2CSK4 (50 ng/ml) for 48 h at 37uC in 200 ml of
RPMI-FBS-10%. The cells were harvested, washed and re-
suspended in binding buffer [0.01 M HEPES (pH 7.4), 0.14 M
NaCl, and 2.5 mM CaCl2]. FITC conjugated Annexin V
antibody (5 ml/tube) and propidium iodide (0.25 mg/5 ml) were
added to the cells. The cells were incubated in dark for 15 minutes
at room temperature. Later, binding buffer (400 ml) was added and
cells were acquired immediately on BD FACS Calibur flowcyt-
ometer using Cell Quest Pro software. Data were analyzed by BD
FACS Diva software.
Microarray analysis
Microarray experiments were done by Genotypic Technology
Pvt. Ltd. (Bangalore, India; www.genotypic.co.in). RB cells from
BALB/c mice were stimulated with Pam2CSK4 (50 ng/ml) in the
presence or absence of anti-CD86 Ab or isotype control (0.5 mg/
106 cells). RNA was isolated, quantified and stored frozen until
use, as described previously (7). The isolated RNA samples were
labeled with Cy-3 using Agilent Quick-Amp labeling kit (p/n5190-
0442) according to manufacturer’s instructions. 800 ng of Cy-3
labeled cRNA samples were fragmented and hybridized on to a
Genotypic designed Custom Whole Genome Mouse 8660 k
(AMADID No: 26986). Fragmentation of labeled cRNA and
hybridization were performed using the gene expression hybrid-
ization kit of Agilent. Hybridization was done in Agilent’s Surehyb
Chambers for 16 h at 65uC. The hybridized slides were washed
using Agilent gene expression wash buffers and scanned with
Agilent microarray scanner (G2505C) at 3 m resolution. Data
extraction from images was done employing Feature extraction
software v 10.5.1.1 of Agilent. Further, feature extracted data were
analyzed using Gene Spring GX v 11 software of Agilent. Genes
were classified based on the functional category and pathways
using software Gene Spring GX and Genotypic Biointerpreter-
Biological Analysis. Microarray data has been submitted to GEO
data base (accession number - GSE28517).
Statistics
The statistical analysis of the data was done by Student’s ‘t’ test,
non-parametric Mann-Whitney two tailed and repeated measure
ANOVA with post Student-Newman-Keuls multiple comparisons
test using Graph Pad InStat 3 software. Statistical analysis of
microarray data was done using one way ANOVA.
Supporting Information
Figure S1 CD86.TLR-2 stimulation augments the pro-
liferation of RB cells. Signaling was delivered in RB cells
isolated from C57BL/6 mice for 24 h with anti-CD86 Ab (0.5 mg/
106cells) and different concentrations of Pam2CSK4. Later, 3H-
thymidine was added and cells were further incubated for
additional 16 h. Cells were harvested and the amount of
radioactivity incorporated was measured by liquid scintillation
counting. Data are represented as the counts per minute (cpm) and
expressed as mean 6 SD from triplicate wells. Results are
indicative of two independent experiments. ‘*’, ‘**’, ‘***’ indicate
p,0.05, p,0.01, p,0.001, respectively.
(TIF)
Figure S2 Concomitant signaling through CD86 and
TLR-2 induces blast formation in resting B cells.
Signaling through CD86 and TLR-2 was delivered in RB cells
with anti-CD86 Ab and Pam2CSK4, either separately or in
conjunction for indicated durations. Bright field images of the
cultures were taken after stipulated durations of stimulation at
4061.6 magnification using a constant exposure time (11.11 sec).
For each combination, 5–6 different fields were imaged. Shown
here are the images from representative of three independent
experiments.
(TIF)
Figure S3 Sequential gating of resting B cells to define
MZP cell subsets. (A) CD19+ lymphocytes were further gated
on the basis of expression of IgD and IgM and defined as follicular
cells I and II (FO I, II), marginal zone cells (MZ) and marginal
zone precursors (MZP). IgDhiIgMhi cells were further differenti-
ated into marginal zone precursors (MZP) on the basis of CD21/
35 and CD23 expression; (B) contour diagrams of marginal zone
precursors in differentially stimulated B cells at indicated time
durations. Values in contour plots indicate the percent populations
of IgDhiIgMhiCD21/35hiCD23hi expressing cells. Data are
representative of three independent experiments.
(TIF)
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